6 news items
Celularity Abstract "Emerging Technologies for the Management and Protection of Tendon Injuries: Decellularized Placental Biomaterials" Accepted at ORS Tendon Conference 2024
CELU
18 Apr 24
regenerative biomaterials business through innovations like this which we believe will significantly contribute to revenue growth. I am confident Celularity's
Celularity Says That Its Expected Net Sales For Q1 2024 Are Trending Ahead Of The Expectations It Announced In February For Its Advanced Biomaterial Products And Biobanking Businesses; Implements Planned 2024 SG&A Reductions And Manufacturing Ramp For Advanced Biomaterial Products
CELU
15 Apr 24
. Celularity's predecessor company was an early innovator in the field of placental-derived biomaterials, and today we continue to develop innovative, next
Celularity Announces Net Sales Trending Ahead of Expectations for First Quarter 2024; Implements Planned 2024 SG&A Reductions and Manufacturing Ramp for Advanced Biomaterial Products
CELU
15 Apr 24
care market and from additional potential applications for our advanced biomaterial products. Celularity's predecessor company was an early innovator
Celularity Receives Healthcare Common Procedure Coding System Q Code Approval From The U.S. Centers For Medicare & Medicaid Services For Biovance 3L
CELU
26 Mar 24
and beyond. We will continue to innovate in this important part of our business and look forward to providing future updates
Celularity CEO to Present on Cell Therapy's Potential to Improve Longevity at 2024 ABUNDANCE Summit
CELU
14 Mar 24
target indications in autoimmune, infectious, and degenerative diseases. In addition, Celularity develops, manufactures, and commercializes innovative
x5zkzc426dnzih45mj64hzggct441srfleio87xdxccwuuj5ue8
CELU
12 Mar 24
and Director of both Brain Technology and Innovation Park and the National Center for Nano-Bio-Electronics. In addition to serving as Celularity's
- Prev
- 1
- Next